Clinical significance of serum CA15-3 as a prognostic parameter during follow-up periods in patients with breast cancer

被引:15
作者
Chu, Won Gong [1 ]
Ryu, Dong Won [1 ]
机构
[1] Kosin Univ, Gospel Hosp, Dept Surg, Div Breast Surg, Busan 49267, South Korea
关键词
Breast neoplasms; CA15-3; Tumor biomarker; Prognosis; CARCINOEMBRYONIC ANTIGEN LEVELS; CA; 15-3; CEA; MARKERS; ASSAY; BIOMARKERS; CA125;
D O I
10.4174/astr.2016.90.2.57
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: To assess the relationship between the kinetics of the serum CA15-3 level and the five-year disease-free survival rate of breast cancer patients. Methods: The subjects of this study, 297 women who were diagnosed with breast cancer, were the subset of patients operated on at Kosin University Gospel Hospital from January 2008 to December 2010. We evaluated the change of serum CA15-3 levels during outpatient follow-up period. The changing patterns of serum CA15-3 level were divided into 5 categories; surge without decline, surge with incidental decline, decline without surge, decline with incidental surge, and no change. Clinicopathologic factors were evaluated for each group. Results: The number of patients in surge without decline, surge with incidental decline, decline without surge, decline with incidental surge, and no changes groups were 30 (10.1%), 85 (28.6%), 80 (26.9%), 73 (24.6%), and 29 (9.7%), respectively. The clinicopathologic characteristics were not significantly different among these groups. The log rank test found that 5-year disease-free survival rate according to the kinetics of serum CA15-3 levels were significant (P = 0.004) particularly for the surge without decline group. Conclusion: According to the findings of this study, the surge without incidental decline pattern of serum CA15-3 levels during the follow-up period is associated with poor prognosis. Significant association was found among changing patterns of serum CA15-3 levels and breast cancer recurrence rate.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 28 条
[1]  
Agha-Hosseini F, 2009, MED ORAL PATOL ORAL, V14, pE521
[2]  
Ali HQ, 2013, J PAK MED ASSOC, V63, P1138
[3]   PROGNOSTIC VALUE IN PREDICTING OVERALL SURVIVAL OF 2 MUCINOUS MARKERS - CA-15-3 AND CA-125 IN BREAST-CANCER PATIENTS AT FIRST RELAPSE OF DISEASE [J].
BERRUTI, A ;
TAMPELLINI, M ;
TORTA, M ;
BUNIVA, T ;
GORZEGNO, G ;
DOGLIOTTI, L .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (14) :2082-2084
[4]   AN ASSESSMENT OF THE CLINICAL USEFULNESS OF 2 SERUM MARKERS, CA 15 3 AND HMFG 2 IN LOCALIZED AND METASTATIC BREAST-CANCER [J].
BLISS, P ;
FISKEN, J ;
ROULSTEIN, J ;
LEONARD, RCF .
DISEASE MARKERS, 1993, 11 (01) :45-48
[5]  
Brooks Mai, 2009, V472, P307, DOI 10.1007/978-1-60327-492-0_13
[6]   COMPARISON OF A NOVEL ASSAY FOR BREAST-CANCER MUCIN TO CA15-3 AND CARCINOEMBRYONIC ANTIGEN [J].
DALY, L ;
FERGUSON, J ;
CRAM, GP ;
HARS, V ;
GEORGE, SL ;
MCCARTY, KS ;
BAST, RC .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1057-1065
[7]   Novel automated flow-based immunosensor for real-time measurement of the breast cancer biomarker CM15-3 in serum [J].
Darwish, Ibrahim A. ;
Wani, Tanveer A. ;
Khalil, Nasr Y. ;
Blake, Diane A. .
TALANTA, 2012, 97 :499-504
[8]   CA15-3, CASA, MSA, AND TPS AS DIAGNOSTIC SERUM MARKERS IN BREAST-CANCER [J].
DEVINE, PL ;
DUROUX, MA ;
QUIN, RJ ;
MCGUCKIN, MA ;
JOY, GJ ;
WARD, BG ;
POLLARD, CW .
BREAST CANCER RESEARCH AND TREATMENT, 1995, 34 (03) :245-251
[9]   Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC) [J].
Di Gioia, Dorit ;
Heinemann, Volker ;
Nagel, Dorothea ;
Untch, Michael ;
Kahlert, Steffen ;
Bauerfeind, Ingo ;
Koehnke, Thomas ;
Stieber, Petra .
TUMOR BIOLOGY, 2011, 32 (04) :777-785
[10]   COMPARISON OF CIRCULATING CA15-3 AND CARCINOEMBRYONIC ANTIGEN LEVELS IN PATIENTS WITH BREAST-CANCER [J].
HAYES, DF ;
ZURAWSKI, VR ;
KUFE, DW .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (10) :1542-1550